210 related articles for article (PubMed ID: 12455036)
1. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis.
Lai HC; Sytwu HK; Sun CA; Yu MH; Yu CP; Liu HS; Chang CC; Chu TY
Int J Cancer; 2003 Jan; 103(2):221-5. PubMed ID: 12455036
[TBL] [Abstract][Full Text] [Related]
2. Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis.
Ueda M; Hung YC; Terai Y; Yamaguchi H; Saito J; Nunobiki O; Noda S; Ueki M
Gynecol Oncol; 2005 Jul; 98(1):129-33. PubMed ID: 15894356
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction.
Lai HC; Lin WY; Lin YW; Chang CC; Yu MH; Chen CC; Chu TY
Gynecol Oncol; 2005 Oct; 99(1):113-8. PubMed ID: 15996722
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of the interferon-gamma gene in cervical carcinogenesis.
Lai HC; Chang CC; Lin YW; Chen SF; Yu MH; Nieh S; Chu TW; Chu TY
Int J Cancer; 2005 Feb; 113(5):712-8. PubMed ID: 15499631
[TBL] [Abstract][Full Text] [Related]
5. Association between human papillomavirus and Epstein - Barr virus DNA and gene promoter methylation of RB1 and CDH1 in the cervical lesions: a transversal study.
McCormick TM; Canedo NH; Furtado YL; Silveira FA; de Lima RJ; Rosman AD; Almeida Filho GL; Carvalho Mda G
Diagn Pathol; 2015 Jun; 10():59. PubMed ID: 26032781
[TBL] [Abstract][Full Text] [Related]
6. Relationship between polymorphisms in the FAS/FASL death receptor system and progression of low-grade precursor lesions infected with high-risk human papilloma virus.
Santaclara V; Torres-Moreno D; Bernal-Mañas CM; Isaac MA; Ortiz-Reina S; Conesa-Zamora P
Hum Immunol; 2021 Sep; 82(9):621-624. PubMed ID: 34127318
[TBL] [Abstract][Full Text] [Related]
7. CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women.
Chatterjee K; Dandara C; Hoffman M; Williamson AL
BMC Cancer; 2010 Jun; 10():278. PubMed ID: 20537184
[TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP 309 human papillomavirus infection in cervical carcinogenesis.
Nunobiki O; Ueda M; Yamamoto M; Toji E; Sato N; Izuma S; Okamoto Y; Torii K; Noda S
Gynecol Oncol; 2010 Sep; 118(3):258-61. PubMed ID: 20538323
[TBL] [Abstract][Full Text] [Related]
9. Soluble interleukin 2 receptor levels and cervical neoplasia: results from a population-based case-control study in Costa Rica.
Ung A; Kramer TR; Schiffman M; Herrero R; Bratti MC; Burk RD; Swanson CA; Sherman ME; Hutchinson ML; Alfaro M; Morales J; Balmaceda I; Hildesheim A
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):249-53. PubMed ID: 10090303
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias.
Lai HC; Lin YW; Chang CC; Wang HC; Chu TW; Yu MH; Chu TY
Gynecol Oncol; 2007 Mar; 104(3):629-35. PubMed ID: 17097722
[TBL] [Abstract][Full Text] [Related]
11. Viral load of episomal and integrated forms of human papillomavirus type 33 in high-grade squamous intraepithelial lesions of the uterine cervix.
Khouadri S; Villa LL; Gagnon S; Koushik A; Richardson H; Matlashewski G; Roger M; Ferenczy AS; Franco EL; Coutlée F
Int J Cancer; 2007 Dec; 121(12):2674-81. PubMed ID: 17708553
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of low and high grade squamous intraepithelial lesions of the cervix: morphologic progression or multiple papillomaviruses?
Park J; Sun D; Genest DR; Trivijitsilp P; Suh I; Crum CP
Gynecol Oncol; 1998 Sep; 70(3):386-91. PubMed ID: 9790792
[TBL] [Abstract][Full Text] [Related]
13. No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ.
Engelmark MT; Renkema KY; Gyllensten UB
Int J Cancer; 2004 Dec; 112(6):1084-5. PubMed ID: 15316939
[No Abstract] [Full Text] [Related]
14. Differential viral loads of human papillomavirus 16 and 58 infections in the spectrum of cervical carcinogenesis.
Lai HC; Peng MY; Nieh S; Yu CP; Chang CC; Lin YW; Sun CA; Chu TY
Int J Gynecol Cancer; 2006; 16(2):730-5. PubMed ID: 16681753
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the association of NKG2C copy number variations with susceptibility to human papillomavirus-induced cervical lesions.
Vilchez JR; Torres-Moreno D; Martínez-Senac MM; Trujillo-Santos J; Conesa-Zamora P
Hum Immunol; 2013 Oct; 74(10):1352-6. PubMed ID: 23911737
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Fas gene promoter polymorphism in cervical cancer patients.
Dybikowska A; Sliwinski W; Emerich J; Podhajska AJ
Int J Mol Med; 2004 Sep; 14(3):475-8. PubMed ID: 15289903
[TBL] [Abstract][Full Text] [Related]
17. Glutathione-S-transferase and p53 polymorphisms in cervical carcinogenesis.
Ueda M; Hung YC; Terai Y; Saito J; Nunobiki O; Noda S; Ueki M
Gynecol Oncol; 2005 Mar; 96(3):736-40. PubMed ID: 15721419
[TBL] [Abstract][Full Text] [Related]
18. Distribution of human papillomavirus genotypes in archival cervical lesions in eastern inner Mongolian autonomous region, China.
Wu EQ; Yu XH; Zha X; Zhang GN; Wang JH; Fan Y; Tang YY; Zhao ZX; Wu YG; Kong W
Int J Gynecol Cancer; 2009 Jul; 19(5):919-23. PubMed ID: 19574785
[TBL] [Abstract][Full Text] [Related]
19. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer.
Lai HC; Chu CM; Lin YW; Chang CC; Nieh S; Yu MH; Chu TY
Gynecol Oncol; 2005 Feb; 96(2):314-9. PubMed ID: 15661214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
